Oral GLP-1 Drug Delivers 16.3% Weight Loss

Structure Therapeutics recently shared new Phase 2 trial results for its once-daily pill, aleniglipron. Patients taking a 180 mg dose lost about 16.3% of their body weight over 44 weeks. This result equals a mean weight loss of roughly 39 pounds compared to those on a placebo. Notably, the study showed that patients continued to lose weight through the final week.

These new findings build on earlier data from late 2025. In that study, the drug helped patients lose 15.3% of their weight in 36 weeks. Furthermore, patients on a lower dose achieved 16.2% weight loss after 56 weeks of treatment. Consequently, these results place aleniglipron among the most effective oral weight loss drugs currently in testing.

Side effects are a major concern for oral weight loss drugs, especially at higher doses. In this trial, the data through 20 weeks showed that the drug is relatively easy for patients to handle. For instance, vomiting rates and the number of people who stopped treatment remained low. Therefore, analysts believe these findings prove that higher doses of the drug are safe for most patients.

The market for obesity drugs is changing quickly as companies look for alternatives to shots. While injectable treatments currently dominate the market, oral pills offer a much simpler option for many people. Along with this, aleniglipron performed better than other oral candidates that showed only 12% weight loss. Thus, many experts believe this pill could become a top choice for doctors and patients.

The CEO of Structure Therapeutics confirmed that the company is talking with potential partners and buyers. Many experts viewed this recent data release as a major trigger for a potential merger. As a result, the company stock price jumped by 9% after the news came out. The company now plans to start a much larger Phase 3 trial later in 2026.

Moving toward oral pills instead of shots is a big step forward for patient care. Taking a pill is much easier for people who do not like using needles every week. Moreover, pills are often easier and cheaper for companies to make than injectable drugs. Accordingly, this could lead to better access for patients if the drug receives final approval.

The FDA has not reviewed aleniglipron yet because it is still in the middle stages of testing. The company must complete a successful Phase 3 trial before it can ask for official approval. Building on this, future studies must prove the drug is safe for the heart over long periods. Federal agencies will also look for evidence that the weight loss lasts for several years.

Aleniglipron works by targeting the same receptors as common weight loss shots. The drug helps people feel full, slows down digestion, and manages insulin levels. These combined actions lead to the impressive weight loss seen in the Phase 2 clinical trials. Given this, the drug could represent a major shift in how people manage their weight in the future.